The amiloride-sensitive endothelial sodium channel and vascular tone

Hypertension

Volumn 61, Issue 5, 2013, Pages 952-954

  Warnock, David G ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; EPITHELIAL SODIUM CHANNEL;

AMINO TERMINAL SEQUENCE; BLOOD VESSEL TONE; CARBOXY TERMINAL SEQUENCE; CYTOSOL; EDITORIAL; ENDOTHELIUM CELL; HUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; SALT INTAKE;

ANIMALS; ENDOTHELIUM, VASCULAR; EPITHELIAL SODIUM CHANNELS; HUMANS; HYPERTENSION; LIDDLE SYNDROME; VASCULAR STIFFNESS;

EID: 84876691199     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.00768     Document Type: Editorial

References (20)

1. Jeggle P, Callies C, Tarjus A, Fassot C, Fels J, Oberleithner H, Jaisser F, Kusche-Vihrog K. Epithelial sodium channel stiffens the vascular endo-thelium in vitro and in Liddle mice. Hypertension. 2013;61:1053-1059.
2. Kusche-Vihrog K, Sobczak K, Bangel N, Wilhelmi M, Nechyporuk-Zloy V, Schwab A, Schillers H, Oberleithner H. Aldosterone and amiloride alter ENaC abundance in vascular endothelium. Pfugers Arch. 2008;455:849-857.
3. Fels J, Oberleithner H, Kusche-Vihrog K. Ménage à trois: aldosterone, sodium and nitric oxide in vascular endothelium. Biochim Biophys Acta. 2010;1802:1193-1202.
4. Kellenberger S, Schild L. Epithelial sodium channel/degenerin family of ion channels: a variety of functions for a shared structure. Physiol Rev. 2002;82:735-767.
5. Canessa CM, Horisberger JD, Rossier BC. Epithelial sodium channel related to proteins involved in neurodegeneration. Nature. 1993;361:467-470.
6. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW. Liddle's syndrome: heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel. Cell. 1994;79:407-414.
7. Studer RA, Person E, Robinson-Rechavi M, Rossier BC. Evolution of the epithelial sodium channel and the sodium pump as limiting factors of aldo-sterone action on sodium transport. Physiol Genomics. 2011;43:844-854.
8. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D, Jaisser F. The endothelial mineralocor-ticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010;24:2454-2463.
9. Warnock DG. Liddle syndrome: an autosomal dominant form of human hypertension. Kidney Int. 1998;53:18-24.
10. Hall JE, Guyton AC, Coleman TG, Mizelle HL, Woods LL. Regulation of arterial pressure: role of pressure natriuresis and diuresis. Fed Proc. 1986;45:2897-2903.
11. Rossier BC. 1996 Homer Smith Award Lecture. Cum grano salis: the epithelial sodium channel and the control of blood pressure. J Am Soc Nephrol. 1997;8:980-992.
12. Ji HL, Zhao RZ, Chen ZX, Shetty S, Idell S, Matalon S. δ ENaC: a novel divergent amiloride-inhibitable sodium channel. Am J Physiol Lung Cell Mol Physiol. 2012;303:L1013-L1026.
13. Liddle GW, Bledsoe T, Coppage WS, Jr. A familial renal disorder simulating primary aldosteronism but with negligible aldoserone secretion. Trans Assoc Am Physicians. 1963;76:199-213.
14. Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, Nowack C, Kolkhof P, Kim SY, Zannad F. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012;14:668-675.
15. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
16. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204-2213.
17. Heran BS, Chen JM, Wang JJ, Wright JM. Blood pressure lowering eff-cacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension. Cochrane Database Syst Rev. 2012;11:CD008167.
18. Hirsh AJ, Molino BF, Zhang J, Astakhova N, Geiss WB, Sargent BJ, Swenson BD, Usyatinsky A, Wyle MJ, Boucher RC, Smith RT, Zamurs A, Johnson MR. Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fbrosis and chronic bronchitis. J Med Chem. 2006;49:4098-4115.
19. Hirsh AJ, Zhang J, Zamurs A, Fleegle J, Thelin WR, Caldwell RA, Sabater JR, Abraham WM, Donowitz M, Cha B, Johnson KB, St George JA, Johnson MR, Boucher RC. Pharmacological properties of N-(3, 5-diamino-6-chloropyrazine-2-carbonyl)- N'-4-[4-(2, 3-dihydroxypropoxy) phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical effcacy for cystic fbrosis lung disease. J Pharmacol Exp Ther. 2008;325:77-88.
20. Forrest G, McInnes GT, Fairhead AP, Thompson GG, Brodie MJ. Simple high-performance liquid chromatographic method for the measurement of amiloride in body fuids. J Chromatogr. 1988;428:123-130.